Innoviva (INVA) Operating Income Growth (5y) (2015 - 2026)

Innoviva (INVA) Operating Income Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,440.76 Bn 66,440.47 Bn -
2 Nanobiotix 1,909.20 Bn 1,909.14 Bn -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn -
4 BeOne Medicines 468.28 Bn 463.49 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.49 Bn 115.24 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.26 Bn 61.51 Bn 3.31 Bn
7 Belite Bio 62.88 Bn 62.88 Bn -
8 Argenx Se 55.67 Bn 50.48 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.37 Bn 34.36 Bn 959.66 Mn
10 Innoviva 1.61 Bn 1.01 Bn 75.83 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 39.11%
Dec 31, 2025 -16.46%
Sep 30, 2025 8.12%
Jun 30, 2025 -8.45%
Mar 31, 2025 -11.45%
Dec 31, 2024 -16.47%
Sep 30, 2024 15.27%
Jun 30, 2024 -1.76%
Mar 31, 2024 -18.35%
Dec 31, 2023 -15.83%
Sep 30, 2023 17.89%
Jun 30, 2023 -20.11%
Mar 31, 2023 -20.42%
Dec 31, 2022 -16.60%
Sep 30, 2022 12.37%
Jun 30, 2022 -20.14%
Mar 31, 2022 -20.16%
Dec 31, 2021 -16.66%
Sep 30, 2021 57.50%
Jun 30, 2021 30.12%